


PHARMACEUTICAL 2020

KalVista Pharmaceuticals Inc. Rank 75 of 362







PHARMACEUTICAL 2020

KalVista Pharmaceuticals Inc. Rank 75 of 362



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 127% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 332% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	115,546
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,052
Liabilities, Non-Current	3,342
Other Assets	173
Other Compr. Net Income	-817
Other Expenses	124
Other Liabilities	0
Other Net Income	9,128
Property and Equipment	2,413
Research and Development	35,021
Revenues	16,127
Selling, General and Administrative Expense	10,926

Output Variable	Value in 1000 USD
Assets	118,132
Liabilities	21,394
Expenses	46,071
Stockholders Equity	96,738
Net Income	-20,816
Comprehensive Net Income	-21,224
Economic Capital Ratio	29%